Get the Stockscreener App
2.05
6.77%
0.13
After Hours:
2.05
Equillium Inc stock is traded at $2.05, with a volume of 646.14K.
It is up +6.77% in the last 24 hours and down -17.00% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$1.92
Open:
$1.91
24h Volume:
646.14K
Relative Volume:
1.30
Market Cap:
$129.61M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-4.0212
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
+13.89%
1M Performance:
-17.00%
6M Performance:
+61.42%
1Y Performance:
+342.76%
1-Day Range:
$1.91
$2.17
1-Week Range:
$1.695
$2.17
52-Week Range:
$0.27
$2.70
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.05 | 121.39M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
[ARS] Equillium, Inc. SEC Filing - Stock Titan
Reverse split and share increase up for Equillium (NASDAQ: EQ) stockholder vote - Stock Titan
Equillium (EQ) price target increased by 10.71% to 7.90 - MSN
Raymond James Initiates Coverage of Equillium (EQ) with Strong Buy Recommendation - MSN
EQ Initiates Coverage On by Raymond James -- Strong Buy Rating A - GuruFocus
Raymond James Initiates Equillium at Strong Buy With $6 Price Target - Moomoo
EQ Initiates Coverage On by Raymond James -- Strong Buy Rating Announced - GuruFocus
Here’s what Roth Capital thinks of Equillium (EQ) stock - MSN
Equillium (EQ) price target increased by 27.27% to 7.14 - MSN
Raymond James initiates Equillium stock coverage with strong buy By Investing.com - Investing.com Australia
Raymond James initiates Equillium stock coverage with strong buy - Investing.com
Chart Watch: Can Equillium Inc lead its sector in growthEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
US Stocks Recap: Whats next for Equillium Inc stock2026 Snapshot & Weekly Setup with High ROI Potential - baoquankhu1.vn
Trade Report: Can Equillium Inc sustain earnings growthWeekly Trend Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Market Pulse: Whats next for Equillium Inc stockWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Equillium Announces Poster Presentations at IMMUNOLOGY2026, the Annual Meeting of the American Association of Immunologists - Bitget
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists - The Manila Times
Equillium Announces Poster Presentations at - GlobeNewswire
Profit Recap: Can Equillium Inc sustain earnings growthMarket Weekly Review & Capital Protection Trading Alerts - baoquankhu1.vn
Aug EndMonth: Can Equillium Inc sustain earnings growthTrade Risk Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Revenue Check: What is the target price for Equillium Inc stockWeekly Trade Analysis & Smart Allocation Stock Tips - baoquankhu1.vn
Equillium Inc selling stockholder may offer up to 18.9 million shares of common stock - marketscreener.com
Equillium (NASDAQ: EQ) registers 18.9M resale shares from RA Capital - Stock Titan
Equillium (EQ) Gains Overweight Rating with Promising Future Prospects - GuruFocus
Cantor Fitzgerald Begins Coverage on Equillium (NASDAQ:EQ) - MarketBeat
Equillium (EQ) Gains Overweight Rating with Promising Future Pro - GuruFocus
Cantor Fitzgerald Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $10 - Moomoo
Breakout Watch: What is the target price for Equillium Inc stock2026 Technical Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Equillium (EQ) price target increased by 120.00% to 5.61 - MSN
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Equillium reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Reverse split range 1-for-2–1-for-20; Equillium (NASDAQ: EQ) seeks 400M cap - Stock Titan
Operating cash flow per share of Equillium, Inc. – LSX:A2N7B3 - TradingView
Cash per share of Equillium, Inc. – LSX:A2N7B3 - TradingView
Equillium Inc. 2025 Financial Review - AlphaStreet
EQUILLIUM ($EQ) Releases Q4 2025 Earnings - Moomoo
[EFFECT] Equillium, Inc. SEC Filing - Stock Titan
Equillium 2025 10-K: Advancing EQ504 AhR Modulator for Autoimmune & Inflammatory Disease Therapies - Minichart
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Equillium Inc - GuruFocus
Equillium Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Equillium Inc. (NASDAQ:EQ) Reports In-Line Q4 Earnings, Highlights Pipeline Progress and Runway into 2029 - ChartMill
Equillium (EQ) Secures Financial Path to 2029, Focuses on Key Dr - GuruFocus
Equillium reports lower-than-expected Q4 net loss - TradingView
Equillium (NASDAQ:EQ) Announces Quarterly Earnings Results - MarketBeat
Equillium (NASDAQ: EQ) expands autoimmune pipeline and raises $65M in private financings - Stock Titan
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Equillium (EQ) shifts to EQ504 focus, raises $85M and funds into 2029 - Stock Titan
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights - globenewswire.com
Here’s What Roth Capital Thinks of Equillium (EQ) Stock - Insider Monkey
Equillium Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Equillium Inc Stock (EQ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Mar 13 '26 |
Sale |
2.50 |
120,312 |
300,816 |
62,586 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):